Department of Toxicology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi 110062, India.
Department of Toxicology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi 110062, India.
Ageing Res Rev. 2024 Jan;93:102134. doi: 10.1016/j.arr.2023.102134. Epub 2023 Nov 25.
According to the facts and figures 2023stated that 6.7 million Americans over the age of 65 have Alzheimer's disease (AD). The scenario of AD has reached up to the maximum, of 4.1 million individuals, 2/3rd are female patients, and approximately 1 in 9 adults over the age of 65 have dementia with AD dementia. The fact that there are now no viable treatments for AD indicates that the underlying disease mechanisms are not fully understood. The progressive neurodegenerative disease, AD is characterized by amyloid plaques and neurofibrillary tangles (NFTs) of abnormally hyperphosphorylated tau protein and senile plaques (SPs), which are brought on by the buildup of amyloid beta (Aβ). Numerous attempts have been made to produce compounds that interfere with these characteristics because of significant research efforts into the primary pathogenic hallmark of this disorder. Here, we summarize several research that highlights interesting therapy strategies and the neuroprotective effects of GLP-1, Sigma, and, AGE-RAGE receptors in pre-clinical and clinical AD models.
根据 2023 年的数据和事实显示，有 670 万 65 岁以上的美国人患有阿尔茨海默病（AD）。AD 的情况已经达到了最高水平，有 410 万人，其中 2/3 是女性患者，大约每 9 个 65 岁以上的成年人中就有 1 个患有 AD 痴呆症。目前尚无可行的 AD 治疗方法这一事实表明，潜在的疾病机制尚未完全了解。AD 是一种进行性神经退行性疾病，其特征是淀粉样斑块和神经纤维缠结（NFTs），由异常过度磷酸化的 tau 蛋白和老年斑（SPs）组成，这是由淀粉样β（Aβ）的积累引起的。由于对这种疾病的主要致病标志进行了大量研究，因此已经进行了许多尝试来生产干扰这些特征的化合物。在这里，我们总结了一些研究，这些研究强调了 GLP-1、Sigma 和 AGE-RAGE 受体在临床前和临床 AD 模型中的有趣治疗策略和神经保护作用。
